Ramucirumab (1 brand name, 1 dosage form, 1 route)
Available dosage forms: INJECTABLE.
Routes of administration: INJECTION.
Brand Names
- CYRAMZA
Contraindications
None
Adverse Reactions
The following serious adverse reactions are described elsewhere in the labeling: Hemorrhage [see Warnings and Precautions (5.1)]. Gastrointestinal Perforations [see Warnings and Precautions (5.2)]. Impaired Wound Healing [see Warnings and Precautions (5.3)]. Arterial Thromboembolic Events [see Warnings and Precautions (5.4)]. Hypertension [see Warnings and Precautions (5.5)]. Infusion-Related Reactions [see Warnings and Precautions (5.6)]. Worsening of Pre-existing Hepatic Impairment [see Warnings and Precautions (5.7)]. Posterior Reversible Encephalopathy Syndrome [see Warnings and Precautions (5.8)]. Proteinuria Including Nephrotic Syndrome [see Warnings and Precautions (5.9)]. Thyroid Dysfunction [see Warnings and Precautions (5.10)].
Mechanism of Action
Ramucirumab is a VEGFR2 antagonist that specifically binds VEGFR2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligand-stimulated activation of VEGFR2, thereby inhibiting ligand-induced proliferation, and migration of human endothelial cells. Ramucirumab inhibited angiogenesis in an in vivo animal model.